2-isopropyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-isopropyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline
• 英文别名: 2-Isopropyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isochinolin；6,7-dimethoxy-2-propan-2-yl-3,4-dihydro-1H-isoquinoline
• 化学式: C₁₄H₂₁NO₂
• 分子量: 235.326
• InChiKey: YVBQRDJJQXIWDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6,7-二甲氧基-3,4-二氢异喹啉 在 硫酸 、 水 、 锌 、 苯 作用下， 生成 2-isopropyl-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline
  参考文献：
  名称：

  2-Alkyl-1,2,3,4-tetrahydroisoquinoline Hydrochlorides¹

  摘要：

  DOI：

  10.1021/ja01276a023

文献信息

• ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080279821A1

  公开（公告）日：2008-11-13

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及具有以下结构的化合物I，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明还涉及含有上述化合物的制药组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者施用含有本发明化合物的制药组合物来治疗受试者的HCV感染的方法。
• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF NON‑ALCOHOLIC STEATOHEPATITIS<br/>[FR] COMPOSÉS ET PROCÉDÉS DESTINÉS AU TRAITEMENT DE LA STÉATOHÉPATITE NON ALCOOLIQUE
  申请人：AVALIV THERAPEUTICS

  公开号：WO2019111225A1

  公开（公告）日：2019-06-13

  Compounds and compositions are provided having the structure of Formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein T, T', U, U', V, W, R1, R2, R3', n, o, o', o'', and o''' are as defined herein. Such compounds are useful for treating liver diseases and abnormal liver conditions, including non-alcoholic steatohepatitis via inhibition of the lysosomal enzyme cathepsin D. Accordingly, a variety of treatment methods are hereby disclosed, including treatment of underlying conditions such as hepatic inflammation, aberrant lipid metabolism, and irregular lysosomal function.

  提供具有Formula (I)结构或其药用可接受的盐、互变异构体或立体异构体的化合物和组合物，其中T、T'、U、U'、V、W、R1、R2、R3'、n、o、o'、o''和o'''如本文所定义。这些化合物可用于治疗肝病和异常肝脏状况，包括通过抑制溶酶体酶蛋白酶D来治疗非酒精性脂肪性肝炎。因此，这里公开了各种治疗方法，包括治疗基础疾病，如肝脏炎症、异常脂质代谢和溶酶体功能异常。
• T-TYPE CALCIUM CHANNEL BLOCKER
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP3053917A1

  公开（公告）日：2016-08-10

  It is an object to provid a novel compound that has an excellent T-type calcium channel inhibitory activity and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. The present invention provides a novel triazinone compound of Formula (I): where each substituent in the formula is defined in detail in the description, and R1 means a hydrogen atom, or a C1-6 alkyl group, etc., E means a 7 to 14-membered non-aromatic fused heterocyclic group, L3 means a C1-6 alkylene group, etc., D means a C6-14 aryyl group or a 5 to 10-membered heteroaryl group each of which is optionally substituted, etc., a tautomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

  本发明提供一种新颖的化合物，具有优异的T型钙通道抑制活性，特别适用于预防或治疗疼痛、慢性肾脏疾病和心房颤动。该新颖的三氮杂酮化合物的化学式如下（I）：其中公式中的每个取代基在描述中有详细定义，R1表示氢原子，或者C1-6烷基等，E表示一个由非芳香性融合杂环组成的7到14成员环，L3表示C1-6烷基链等，D表示一个C6-14芳基或者一个5到10成员杂环基，每个基都可以选择性取代等，化合物的互变异构体，或其药学上可接受的盐，或其溶剂化合物。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：METHYLGENE INC

  公开号：WO2004069823A1

  公开（公告）日：2004-08-19

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  该发明涉及抑制组蛋白去乙酰化酶的技术。该发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。
• THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS
  申请人：Fink M. David

  公开号：US20070004695A1

  公开（公告）日：2007-01-04

  The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D 4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D 4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

  这些化合物属于类别为噻唑异噁唑基和噻吩吡唑基苯氧基取代的丙基衍生物，可用作D4受体拮抗剂。这些化合物可用于治疗通过抑制D4受体介导的医疗状况。这些状况包括例如注意力缺陷多动障碍、强迫症、精神病、物质滥用、物质依赖、帕金森病、帕金森综合症、迟发性运动障碍、吉尔·德·拉·图雷特综合症、行为障碍和反抗行为障碍。发明的另一个方面是提供一种制药组合物、中间体和制备该类化合物的方法。